Asgard Therapeutics is developing the world’s first cancer immunotherapy based on cell reprogramming. We seek the next leap forward in immunotherapy employing Asgard’s proprietary technology to render cancer cells visible to the immune system in order to attack and eliminate them. This strategy disruptively combines cell reprogramming and immunotherapy, leading to the development of TrojanDC, a novel gene therapy to unleash the immune system on the cancer. TrojanDC will be initially developed for one type of cancer and later applied to other types, opening avenues for revolutionising cancer treatment.
Menu